Title : Population Pharmacokinetic Modeling After Repeated Administrations of RBP-6000, a New, Subcutaneously Injectable, Long-Acting, Sustained-Release Formulation of Buprenorphine, for the Treatment of Opioid Use Disorder.

Pub. Date : 2016 Jul

PMID : 26479717






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Population Pharmacokinetic Modeling After Repeated Administrations of RBP-6000, a New, Subcutaneously Injectable, Long-Acting, Sustained-Release Formulation of Buprenorphine, for the Treatment of Opioid Use Disorder. Buprenorphine SURP and G-patch domain containing 1 Homo sapiens
2 RBP-6000 is a novel sustained-release formulation of buprenorphine for the treatment of opioid use disorder, which has been designed for once-monthly (28 days) subcutaneous (SC) injections. Buprenorphine SURP and G-patch domain containing 1 Homo sapiens
3 A population pharmacokinetic (PK) model was developed to describe the time course of buprenorphine plasma concentrations after repeated SC injections of RBP-6000 at 50 mg, 100 mg, 200 mg, or 300 mg in treatment-seeking opioid-dependent subjects previously on sublingual buprenorphine (Subutex( ) ) treatment. Buprenorphine SURP and G-patch domain containing 1 Homo sapiens